Philip Dayle acts for four patients in the UK Infected Blood Inquiry

Wed, 26 Sep 2018

Philip Dayle of No5 Barristers’ Chambers is currently involved in the UK Infected Blood Inquiry, the national investigation into how thousands of NHS patients were given infected blood products during the 1970s and 1980s.

Mr Dayle is acting for four men who contracted HIV and hepatitis C through contaminated blood products used in the treatment of their haemophilia.

The public inquiry, into what has been described as the worst-ever NHS treatment disaster, opened this week with a commemoration service in honour of those infected and affected by this scandal. The inquiry later heard opening statements from Core Participants, including various government departments 

More than 4,500 British men, women and children are thought to have been treated with contaminated blood products, with around half subsequently dying.

Chaired by retired judge Sir Brian Langstaff, the inquiry will seek to establish the truth about how this scandal happened. It will also investigate whether there has been a cover up since these events occurred more than thirty years ago. 

Mr Dayle is instructed by Cyrilla Davies Knight of Hudgells Solicitors and led by Karon Monaghan QC of Matrix Chambers.

The UK Infected Blood Inquiry is expected to last for more than a year. 

Philip Dayle is a member of the following groups at No5 Barristers’ Chambers: Commercial Litigation; Court of Protection; Education Law; Inquests, Public Inquiries and Coronial Law; International Human Rights; Prison Law; Public Law; and Regulatory and Licensing.

View Philip Dayle’s profile here: http://www.no5.com/barristers/barrister-details/409-philip-dayle/

Related articles

The inquest into the death of Kevin Clinton found multiple failings by staff on Coral Ward, Luton operated by the East London NHS Foundation Trust....

Date: Thu, 16 Mar 2023
On 6th and 7th February 2023 the Administrative Court heard the judicial review of the Secretary of State’s alleged failure to address the evidence of risks to human health posed by 5G technology....

Date: Wed, 08 Feb 2023
In Re A (Covert medication: Closed Proceedings) [2022] EWCOP 44...

Date: Fri, 09 Dec 2022